http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Virpax Pharmaceuticals (VRPX) Files Provisional Patent Application for NSAID Formulation and Method
-
Virpax Pharmaceuticals Files Provisional Patent Application for NSAID Formulation and Method
-
Virpax Pharmaceuticals, Inc. to Ring NASDAQ Closing Bell on July 24, 2023
-
Virpax Pharmaceuticals (VRPX) Files Provisional Patent Application for Intranasal Delivery
-
Virpax Pharmaceuticals Files Provisional Patent Application for Intranasal Delivery
-
Virpax Pharmaceuticals (VRPX) Enters into CRADA with the National Advisory Neurological Disorders and Stroke Council
-
Virpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke Council
-
Virpax Pharmaceuticals (VRPX) Announces CFO Transition
-
Virpax Pharmaceuticals Announces CFO Transition
-
Virpax Pharmaceuticals to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
-
Virpax Pharmaceuticals Reports 2023 First Quarter Results and Recent Developments
-
Virpax Pharmaceuticals To Present at Upcoming CB Tech Watch Seminar
-
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference May 10-11, 2023
-
Virpax Pharmaceuticals (VRPX) Engages Dr. Pardeep Gupta for Development of Probudur
-
Virpax Pharmaceuticals Engages Dr. Pardeep Gupta to Assist in Development of Company’s Lead Asset, Probudur™
-
Virpax Pharmaceuticals (VRPX) Reports on Progress of Envelta
-
Virpax Reports on Progress of Envelta™
-
Virpax Pharmaceuticals (VRPX) Appoints Barbara A. Ruskin to its Board
-
Virpax Pharmaceuticals Announces Appointment of Barbara A. Ruskin, Ph.D, J.D. to the Board of Directors
-
Virpax Pharmaceuticals (VRPX) Reports FY22 Results
-
Virpax Pharmaceuticals Reports 2022 Year-End Results
-
Virpax Pharmaceuticals (VRPX) Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology
-
Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)
-
Virpax Pharmaceuticals (VRPX) Engages New England Investors to Direct Licensing Strategy for Envelta in China
-
Virpax Pharmaceuticals Engages New England Investors to Direct Licensing Strategy for Envelta™ in China

